Alginate Oligomers Enhance CFTR Modulator Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CFTR dysfunction, particularly in cystic fibrosis and related conditions, are limited in effectively addressing the underlying cause of abnormal mucus and ion channel dysfunction, with existing CFTR modulators facing challenges in reaching epithelial cells due to the barrier effect of abnormal mucus and being less effective in patients with a well-established pathological phenotype.
Innovation Solution
The use of alginate oligomers in combination with CFTR modulators, such as lumacaftor, to enhance the therapeutic effects by improving bioavailability and allowing more effective administration routes, including inhalation, and potentially reversing the pathological phenotype of abnormal mucus, thereby increasing the effectiveness of CFTR modulators.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFTR modulators are administered to treat CFTR dysfunction, then ion channel function is improved, but the abnormal mucus barrier prevents effective delivery to epithelial cells
Solution Approach 1:
Alginate oligomers serve as an intermediary substance that modifies the abnormal mucus properties, enabling CFTR modulators to penetrate through the mucus barrier and reach epithelial cells effectively. The alginate oligomers interact with the mucus to reduce its barrier function while allowing the therapeutic agent to pass through.
Solution Approach 2:
The invention changes the physical-chemical parameters of the mucus by introducing alginate oligomers, which modify mucus viscosity, structure, or composition. This parameter change reduces the barrier effect of the mucus, allowing CFTR modulators to reach their target more effectively.
2Reliability
If CFTR modulators are used in patients with well-established pathological phenotype, then treatment is attempted, but responsiveness is poor due to established pathology
Solution Approach 1:
Alginate oligomers are administered beforehand or concurrently with CFTR modulators to preliminarily modify the mucus environment and reduce the barrier effect. This preliminary action prepares the pathway for the CFTR modulator to reach epithelial cells even in patients with established pathology.
Solution Approach 2:
Alginate oligomers act as a mediator that bridges the gap between the CFTR modulator and the epithelial cells in patients with established pathological phenotype. The mediator facilitates drug delivery despite the stable pathological state.
3Ease of operation
If conventional administration routes are used for CFTR modulators, then treatment is simplified, but bioavailability is reduced due to mucus barrier
Solution Approach 1:
Alginate oligomers serve as a mediator that enables conventional administration routes to achieve improved bioavailability. By modifying the mucus barrier properties, the intermediary allows the CFTR modulator to be absorbed more effectively through the same administration route.
Solution Approach 2:
The introduction of alginate oligomers changes the parameters of the mucus layer, reducing its resistance to drug penetration. This parameter change increases the bioavailability of CFTR modulators without requiring complex alternative administration routes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy of alginate oligomers with CFTR modulators enhances the remedial effects on CFTR dysfunction, improves bioavailability, and allows for more effective treatment of patients with established CFTR dysfunction, including those poorly responsive to CFTR modulators, by reducing mucus viscosity and improving ion channel function.
Implementation Method 1
reversing the pathological phenotype of abnormal mucus, thereby increasing the effectiveness of CFTR modulators
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention provides a method for the treatment of a condition in a subject arising from or associated with CFTR dysfunction, said method comprising administering to said subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. In certain embodiments said condition is cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication thereof.